Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1 - Wikidata - awgldk - TriplyDB

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1

http://www.wikidata.org/entity/Q31145823

about

Management of antipsychotic-related weight gain Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs An overview of diabetes management in schizophrenia patients: office based strategies for primary care practitioners and endocrinologists Diabetic db/db mice exhibit central nervous system and peripheral molecular alterations as seen in neurological disorders A review of modafinil and armodafinil as add-on therapy in antipsychotic-treated patients with schizophrenia.Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia Using Non-experimental Data to Estimate Treatment Effects Care provided by general practitioners to patients with psychotic disorders: a cohort study Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders Atypical antipsychotics and metabolic syndrome in patients with schizophrenia: risk factors, monitoring, and healthcare implications.Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study.Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.APOA-I: a possible novel biomarker for metabolic side effects in first episode schizophrenia.Prevalence of metabolic syndrome among patients with schizophrenia in Palestine.Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients Barriers and facilitators to implementation of a metabolic monitoring protocol in hospital and community settings for second-generation antipsychotic-treated youth.Metabolome in schizophrenia and other psychotic disorders: a general population-based study.Alternative methods for testing treatment effects on the basis of multiple outcomes: simulation and case study.A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label study Metabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychotics Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach.Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood-stabilizers.Metabolic status and resistin in chronic schizophrenia over a 2-year period with continuous atypical antipsychotics.Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.Anthropometric parameters as indicators of metabolic derangements in schizophrenia patients stabilized on olanzapine in an Indian rural population Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia.Evaluating the clinical and cost effectiveness of a behaviour change intervention for lowering cardiovascular disease risk for people with severe mental illnesses in primary care (PRIMROSE study): study protocol for a cluster randomised controlled t A pilot study investigating tumor necrosis factor-α as a potential intervening variable of atypical antipsychotic-associated metabolic syndrome in bipolar disorder.Cardiometabolic consequences of therapy for chronic schizophrenia using second-generation antipsychotic agents in a medicaid population: clinical and economic evaluation Association Between Antipsychotic Treatment and Advanced Diabetes Complications Among Schizophrenia Patients With Type 2 Diabetes Mellitus.A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice Is Metabolic Syndrome On the Radar? Improving Real-Time Detection of Metabolic Syndrome and Physician Response by Computerized Scan of the Electronic Medical Record Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.

P2860

Q24610124-E7EC31B1-C957-4C66-A6CC-070A0F7B6F0F Q24630309-74248973-AA04-4362-AF14-273A62F264A9 Q26859927-D3B0EE9E-D9D3-48FD-B36D-BD090D5E108E Q28683010-2244F241-917E-4C70-9FE5-1D825971E49E Q30450336-04C0C8F0-A6A0-4DFB-8AAD-5D5A6EA8855E Q33499547-FAA8692D-41B7-44F5-82E4-39133F5BE8C0 Q33610053-6A71F3FF-6F87-4F76-ADBA-75B5EB63A576 Q33756112-1DD3B800-E12F-43F5-94B6-10BBE3CC766F Q33776187-E1F4B24B-D5A8-4497-BBE3-619EE77286CD Q33802927-911C01BD-D628-40D8-B32B-7B94A7C43C06 Q33928935-68007B97-9E35-4ABF-965E-E111C9230DDA Q33935882-C21B16BC-9F8E-40AF-8747-EF7EA2B6160A Q34187457-BE870222-C743-4492-860A-030DE516B2A7 Q34213209-7332CB40-E3A2-4DA6-A4BC-45187DAD711F Q34414069-E18C3730-059A-4412-B3FE-BA6BF45BC86C Q34523972-3C45AECA-3E3B-44E1-A9E7-DE962CC6E0E1 Q34604314-D4ED82F5-19E9-494F-A849-1445F2E241EF Q34623350-CFC1C36A-C46B-4C31-B63B-107524E6DF50 Q34646095-1BD47112-C792-4146-8B59-C33CEDDDB39D Q34661651-A9424041-C8A5-4319-9636-F80C482D9814 Q34900812-351C1731-B770-463A-A9AD-01332F659EAC Q34971495-7005C6D8-B82E-46DC-8DE2-4655454B55F7 Q35048398-9FAD6CCE-FCC5-4170-A7C1-FD39DA2697AB Q35156543-080C6D23-F589-41BD-8F15-B35F85CF264B Q35191252-F9B152A0-0158-447E-860F-7AC8D9B10525 Q35330607-B62DBE8A-7149-48A5-AE09-CDE3AA58CF5A Q35375788-4563EE74-9DE3-4EE6-B40D-CAB8709DC391 Q35731977-B5926CE1-BB3D-4478-9504-0E0ED6F8F3DE Q36088018-7902F332-FF64-47C6-A579-6E7F67F3ECE2 Q36211690-278499E6-4B51-49AD-91F4-4A6ED6AD9BEC Q36383322-AA4D18BC-50D1-4074-9C52-F835709AE18B Q36420353-60B47EEA-465E-4761-B3A6-9E7CA1C59256 Q36555343-A70F88A6-32C5-4A75-AC1A-FC1751ACF0C7 Q36574892-4415140D-9124-4715-A72D-005D757A1C8A Q36759102-B7F5FF46-9655-4D15-B47A-4FDFDD72B3B5 Q36771558-38837088-F025-44D7-8771-46B1A18D0FE8 Q36817257-B2158C45-3C1D-4FA5-B2F5-BFAE2884D3BC Q36843480-2885156E-D697-43D7-A4E0-44B6645471F9 Q36921831-18D8CA7A-9269-4FCE-924E-C8597A30A4CA Q36973177-E9AF7D82-4B04-444F-BA1F-3A5669110EEB

P2860

Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1

http://www.wikidata.org/entity/Q31145823

description

2008 nî lūn-bûn

@nan

2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Change in metabolic syndrome p ...... prospective data from phase 1

@ast

Change in metabolic syndrome p ...... prospective data from phase 1

@en

type

label

Change in metabolic syndrome p ...... prospective data from phase 1

@ast

Change in metabolic syndrome p ...... prospective data from phase 1

@en

prefLabel

Change in metabolic syndrome p ...... prospective data from phase 1

@ast

Change in metabolic syndrome p ...... prospective data from phase 1

@en

P1433

Q31145823-D865F3C6-0C81-48D0-9DFB-CA90A29EBE8C

P1476

Q31145823-231D206C-3247-46B5-BB3C-DC4EE55B4655

P2093

Q31145823-03568714-A522-4D9C-8A81-A483F2622B5A

Q31145823-03E8DC73-2AEE-42BF-B606-0E4B69B85787

Q31145823-0482AA1E-B53E-4C17-B2BC-14DD1C02A787

Q31145823-7CA2493F-4DE4-435D-A997-3752396C123E

Q31145823-86903BBC-6597-4E65-B144-86452E1491CE

Q31145823-8FA15CEA-6A9E-4202-9BC1-3903BB262D39

Q31145823-D22A6EE3-73FE-4909-AA0B-68DC7B289C88

Q31145823-DD42FEE4-BD69-4A40-890B-EB9812F43106

Q31145823-EEB1F12A-642E-4E71-A527-4EE0964A3200

Q31145823-FDE286B0-9166-4328-9D8F-A65628774916

P2860

Q31145823-05A8364D-498D-4B86-93F1-05D0D91700A6

Q31145823-0C2BC47F-4A23-4F31-867B-3FCFEB6D1A73

Q31145823-13C8E5C1-9EA1-4F15-8D82-9B1EA98D5BE6

Q31145823-15C9A70E-BA0B-49D8-9A50-6D9CCCF9D146

Q31145823-17DDAB89-BC50-40DD-871D-05E2361CEEB8

Q31145823-1B7B2979-D635-4742-B58F-32E433874B76

Q31145823-20A6BC5B-6AF3-49F3-8270-DEF14AD0FE5E

Q31145823-238698AF-992D-481D-8B8A-94B03F32475E

Q31145823-281586ED-8F4C-4A43-A8AE-8FBF75E9C51F

Q31145823-3CDD9079-84F3-46DC-A3D7-64EB33724A9D

P304

Q31145823-5A2B72A4-BB3A-47C0-8324-853928FDA712

P31

Q31145823-2B83D5E4-514B-41C2-AE9E-68BD0E6B7267

P356

Q31145823-1C606CCF-01A8-466C-A43D-955937E6EFF0

P407

Q31145823-0EA1AF21-8E15-4C5D-9402-F0D845603EF0

P433

Q31145823-CC73EABE-0ADE-45D8-B34F-A1A768FB19E1

P478

Q31145823-A59EA264-8611-41B1-9095-2DC0020C75BC

P50

Q31145823-72EB4BF3-F263-4B98-9C96-8CCEB9FDAACE

Q31145823-AC2D3CDE-502B-4218-9B18-A1E8DF58FB5D

P577

Q31145823-DA09132E-4A89-453B-B5C0-34E5932DCAB9

P5875

Q31145823-71BCDA3D-65B5-4929-AD74-8B9805917856

P698

Q31145823-F00E8426-3CA9-4316-AD9D-47BF430B6475

P921

Q31145823-1CC6B5A0-E084-417B-98DF-09489D39C9F1

Q31145823-3403F6EC-66C4-4B20-AC0D-092D3C35EBCA

Q31145823-ED2ECEDC-5051-408E-9FC3-2627D8FACD76

P932

Q31145823-1C5C6574-C00F-4DA6-97EF-D58F1339A127

P356

J.SCHRES.2007.12.487

P1433

Schizophrenia Research

P1476

Change in metabolic syndrome p ...... prospective data from phase 1

@en

P2093

Gail L Daumit

http://www.w3.org/2001/XMLSchema#string

Henry A Nasrallah

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Lieberman

http://www.w3.org/2001/XMLSchema#string

John Hsiao

http://www.w3.org/2001/XMLSchema#string

Jonathan M Meyer

http://www.w3.org/2001/XMLSchema#string

Joseph P McEvoy

http://www.w3.org/2001/XMLSchema#string

Marvin S Swartz

http://www.w3.org/2001/XMLSchema#string

Sonia M Davis

http://www.w3.org/2001/XMLSchema#string

T Scott Stroup

http://www.w3.org/2001/XMLSchema#string

Vicki G Davis

http://www.w3.org/2001/XMLSchema#string

P2860

A Systematic Review of Mortality in Schizophrenia

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

Diagnosis and classification of diabetes mellitus

Banting lecture 1988. Role of insulin resistance in human disease

Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Physical health monitoring of patients with schizophrenia.

The metabolic syndrome: requiescat in pace.

P304

273-286

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.SCHRES.2007.12.487

http://www.w3.org/2001/XMLSchema#string

P407

P433

1-3

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

Robert A. Rosenheck

P577

2008-02-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5594647

http://www.w3.org/2001/XMLSchema#string

P698

18258416

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

metabolic syndrome

P932

3673564

http://www.w3.org/2001/XMLSchema#string